Pyroptosis Inhibition Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Pyroptosis Inhibition Therapy</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Dapansutrile (OLT1177)</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>GSDMD</td>
</tr>
</table>
Last Updated: 2026-03-14 PT
Pathway Diagram
flowchart TD
N0["PYROPTOSIS"]
N1["NLRP3"]
N1 -->|"activates"| N0
N2["Als"]
N2 -->|"activates"| N0
N3["Inflammation"]
N3 -->|"activates"| N0
N4["Cancer"]
N4 -->|"therapeutic target"| N0
N0 -->|"activates"| N2
N5["Apoptosis"]
N0 -->|"activates"| N5
N6["Autophagy"]
N0 -->|"regulates"| N6
N0 -->|"activates"| N0
N5 -->|"activates"| N0
N6 -->|"regulates"| N0
N1 -->|"activates"| N0
N7["Inflammasome"]
N0 -->|"activates"| N7
Introduction
...Pyroptosis Inhibition Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Pyroptosis Inhibition Therapy</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Dapansutrile (OLT1177)</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>GSDMD</td>
</tr>
</table>
Last Updated: 2026-03-14 PT
Pathway Diagram
Mermaid diagram (expand to render)
Introduction
Pyroptosis inhibition therapy represents a promising therapeutic strategy for neurodegenerative diseases, targeting the inflammatory cell death pathway known as pyroptosis. This form of programmed cell death is characterized by gasdermin D (GSDMD)-mediated pore formation, leading to cellular swelling, membrane rupture, and the release of pro-inflammatory cytokines including interleukin-1β (IL-1β) and interleukin-18 (IL-18) [1](https://pubmed.ncbi.nlm.nih.gov/32877962/). Pyroptosis has emerged as a critical driver of neuroinflammation in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), making pyroptosis inhibition a compelling therapeutic target [2](https://pubmed.ncbi.nlm.nih.gov/32084335/). [@shi2017]
Mechanism of Action
The Pyroptosis Pathway
Pyroptosis is initiated by inflammasome activation, primarily involving NLRP3 (NOD-like receptor family pyrin domain containing 3), which senses pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [3](https://pubmed.ncbi.nlm.nih.gov/31248645/). Upon activation, NLRP3 recruits the adaptor protein ASC (PYCARD) and pro-caspase-1, forming the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) complex. [@liu2020]
The canonical pyroptosis pathway involves: [@he2019]
Inflammasome Activation: NLRP3 senses cellular stress signals, including amyloid-β plaques in AD [4](https://pubmed.ncbi.nlm.nih.gov/29179163/) and [α-synuclein](/proteins/alpha-synuclein) aggregates in PD [5](https://pubmed.ncbi.nlm.nih.gov/31740847/).
Caspase-1 Activation: Pro-caspase-1 is cleaved into active caspase-1, which then processes pro-IL-1β and pro-IL-18 into their mature, secreted forms [1](https://pubmed.ncbi.nlm.nih.gov/32877962/).
Gasdermin D Cleavage: Active caspase-1 cleaves gasdermin D (GSDMD) at Asp275 (human) or Asp276 (mouse), generating the N-terminal fragment (GSDMD-N) that oligomerizes and forms pores in the plasma membrane [6](https://pubmed.ncbi.nlm.nih.gov/26513298/).
Pore Formation and Cell Death: GSDMD-N pores (10-20 nm diameter) cause cellular swelling, membrane rupture, and release of intracellular contents including IL-1β, IL-18, and alarmins [7](https://pubmed.ncbi.nlm.nih.gov/26375059/).Non-Canonical Pyroptosis
In human macrophages and [neurons](/entities/neurons), caspase-4, caspase-5 (in humans), and caspase-11 (in mice) can directly recognize intracellular lipopolysaccharide (LPS) and cleave GSDMD, initiating non-canonical pyroptosis [8](https://pubmed.ncbi.nlm.nih.gov/24213625/). This pathway may be relevant in neurodegenerative diseases where bacterial or viral infections may trigger neuroinflammation. [@heneka2013]
Therapeutic Targets
1. NLRP3 Inflammasome Inhibitors
The NLRP3 inflammasome represents a primary therapeutic target for pyroptosis inhibition: [@gao2021]
- MCC950: A potent small-molecule NLRP3 inhibitor that blocks ASC speck formation and IL-1β production [9](https://pubmed.ncbi.nlm.nih.gov/26403631/). MCC950 has demonstrated neuroprotective effects in AD mouse models, reducing amyloid-β burden and improving cognitive function [10](https://pubmed.ncbi.nlm.nih.gov/31039447/).
- Dapansutrile (OLT1177): A β-sulfonyl nitrile compound that selectively inhibits NLRP3 and is in clinical development for inflammatory diseases [11](https://pubmed.ncbi.nlm.nih.gov/29249813/).
- Curcumin and Natural Compounds: Various natural compounds including curcumin, resveratrol, and epigallocatechin-3-gallate (EGCG) have shown NLRP3 inhibitory activity in preclinical models [12](https://pubmed.ncbi.nlm.nih.gov/29158934/).
2. Caspase-1 Inhibitors
- VX-765: A selective caspase-1 inhibitor that has shown efficacy in preclinical models of AD and ALS [13](https://pubmed.ncbi.nlm.nih.gov/19502875/).
- Pralnacasan (VX-740): An oral caspase-1 inhibitor that progressed to clinical trials for rheumatoid arthritis before being discontinued [14](https://pubmed.ncbi.nlm.nih.gov/14519148/).
3. Gasdermin D Inhibitors
- Disulfiram: An aldehyde dehydrogenase inhibitor approved for alcohol use disorder that also inhibits GSDMD-mediated pyroptosis [15](https://pubmed.ncbi.nlm.nih.gov/31650960/).
- Dimethyl fumarate (Tecfidera): An FDA-approved drug for multiple sclerosis that alkylates GSDMD and blocks pyroptosis [16](https://pubmed.ncbi.nlm.nih.gov/32089444/).
Preclinical Evidence in Neurodegenerative Diseases
Alzheimer's Disease
Multiple studies support a role for pyroptosis in AD pathogenesis: [@shi2015]
- NLRP3 inflammasome activation has been observed in [microglia](/cell-types/microglia-neuroinflammation) surrounding amyloid-β plaques in AD brain tissue [4](https://pubmed.ncbi.nlm.nih.gov/29179163/).
- Genetic deletion of NLRP3 or caspase-1 in [APP](/entities/app-protein)/PS1 mice reduces neuroinflammation, improves synaptic plasticity, and enhances cognitive function [10](https://pubmed.ncbi.nlm.nih.gov/31039447/).
- GSDMD-mediated pyroptosis contributes to neuronal loss in AD, and GSDMD deficiency protects against memory deficits in mouse models [17](https://pubmed.ncbi.nlm.nih.gov/33268894/).
Parkinson's Disease
- NLRP3 activation is observed in substantia nigra dopaminergic neurons in PD patients and animal models [5](https://pubmed.ncbi.nlm.nih.gov/31740847/).
- α-Synuclein fibrils activate NLRP3 inflammasome in microglia, and inhibiting this pathway protects against dopaminergic neurodegeneration [18](https://pubmed.ncbi.nlm.nih.gov/29712925/).
- Caspase-1 inhibition reduces motor deficits and protects dopaminergic neurons in MPTP and 6-OHDA models of PD [19](https://pubmed.ncbi.nlm.nih.gov/28719147/).
Amyotrophic Lateral Sclerosis
- NLRP3 and GSDMD are activated in ALS patient spinal cord tissue and in SOD1-G93A mouse models [20](https://pubmed.ncbi.nlm.nih.gov/29429673/).
- MCC950 delays disease onset and extends survival in SOD1-G93A ALS mice by inhibiting microglial pyroptosis [21](https://pubmed.ncbi.nlm.nih.gov/32344567/).
- GSDMD deficiency reduces microglial activation and motor neuron loss in ALS models [22](https://pubmed.ncbi.nlm.nih.gov/33268894/).
Clinical Trial Status
Currently, no NLRP3 inhibitors or pyroptosis inhibitors have been approved for neurodegenerative diseases. However, several compounds are in various stages of clinical development: [@liu2016]
Several clinical trials are evaluating anti-inflammatory therapies in AD and PD that may indirectly inhibit pyroptosis: [@boxer2010]
- NCT05638295: Evaluating NLRP3 inflammasome markers in AD patients
- NCT05424251: Testing anti-inflammatory therapy in early PD
Safety Profile
The safety profile of pyroptosis inhibitors varies by compound: [@raren2004]
- MCC950: Generally well-tolerated in preclinical studies; potential liver toxicity requires monitoring in long-term use [9](https://pubmed.ncbi.nlm.nih.gov/26403631/).
- Dimethyl fumarate: FDA-approved with known side effects including flushing, gastrointestinal symptoms, and lymphopenia requiring monitoring [16](https://pubmed.ncbi.nlm.nih.gov/32089444/).
- Caspase-1 inhibitors: Potential immunosuppression risk due to broad inhibition of inflammatory cytokine production [14](https://pubmed.ncbi.nlm.nih.gov/14519148/).
Cross-Links to Related Pages
- [Neuroinflammation](/mechanisms/neuroinflammation) - The broader inflammatory context in which pyroptosis occurs
- [Alzheimer's Disease](/diseases/alzheimers-disease) - Primary target indication
- [Parkinson's Disease](/diseases/parkinsons-disease) - Primary target indication
- [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) - Primary target indication
- [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome) - Key upstream activator
- [Microglia](/cell-types/microglia) - Primary cell type where pyroptosis occurs in the brain
- [Innate Immune System](/mechanisms/innate-immune-response) - Broader immune context
- [Cytokines in Neurodegeneration](/mechanisms/cytokines-neurodegeneration) - IL-1β and IL-18 as downstream effectors
- [Neuroprotective Strategies](/therapeutics/neuroprotection) - Therapeutic context
Future Directions
Key areas for future research include: [@hu2020]
[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Developing NLRP3 inhibitors with adequate CNS penetration
Biomarker development: Identifying biomarkers to monitor pyroptosis inhibition in clinical trials
Combination therapy: Exploring combinations with disease-modifying therapies targeting amyloid, [tau](/proteins/tau), or α-synuclein
Patient stratification: Identifying patients with elevated pyroptosis markers who may benefit most from this approachSee Also
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
- [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)
- [Innate Immune System](/mechanisms/innate-immune-response)
- [Cytokines in Neurodegeneration](/mechanisms/cytokines-neurodegeneration)
- [Neuroprotective Strategies](/therapeutics/neuroprotection)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Additional evidence sources: [@humphries2020] [@tan2021] [@gordon2018] [@zhang2019] [@johanna2020] [@clementi2020] [@liu2021]
Actionable Next Steps
Lab Experiments
GSDMD inhibitor screening: Identify selective GSDMD inhibitors that block pyroptosis without impairing host defense
Biomarker development: Establish plasma IL-18, IL-1β as pharmacodynamic markers for pyroptosis inhibition
Combination testing: Test pyroptosis inhibitors combined with anti-amyloid immunotherapiesClinical Protocol Design
Enrichment strategy: Select patients with elevated inflammatory biomarkers (CSF IL-1β, IL-18)
Dose-finding design: Escalating dose with inflammatory marker monitoring
Safety monitoring: Track infection rates (pyroptosis is host defense mechanism)Company Partnership Opportunities
Eli Lilly: Has inflammation pipeline; potential partner
Ventus Therapeutics: GSDMD inhibitor program
NodThera: NLRP3/GSDMD pipelineImplementation Roadmap
Phase 1: Target Validation (Months 1-12)
- Activities: GSDMD inhibitor identification, IND-enabling studies
- Cost: $4-6M
- Go/No-Go: Lead compound with pyroptosis inhibition
Phase 2: Clinical Development (Months 12-36)
- Activities: Phase 1/2 trial in early AD/PD
- Cost: $12-20M
- Go/No-Go: Safety; inflammatory marker reduction
Phase 3: Registration (Months 36-60)
- Activities: Pivotal trial
- Cost: $30-50M
- Endpoints: Cognitive endpoints, inflammatory biomarkers
Total Program Cost: $46-76M over 60 months
References
[Shi J, et al., Pyroptosis: Gasdermin-mediated programmed necrotic cell death. Trends in Biochemical Sciences (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/32877962/)
[Liu TG, et al., Pyroptosis: A novel therapeutic target for neurodegenerative diseases. CNS Neuroscience & Therapeutics (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32084335/)
[He Y, et al., NLRP3 inflammasome: structure, function, and targeting. Pharmacological Reviews (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31248645/)
[Heneka MT, et al., NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/29179163/)
[Gao L, et al., Activation of the NLRP3 inflammasome in Parkinson's disease: A meta-analysis. Frontiers in Neuroscience (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/31740847/)
[Shi J, et al., Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26513298/)
[Liu X, et al., Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26375059/)
[Kayagaki N, et al., Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24213625/)
[Coll RC, et al., A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26403631/)
[Dempsey C, et al., NLRP3 inflammasome inhibition improves cognition and reduces Alzheimer-like pathology. Nature (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31039447/)
[Unknown, O'Neill LAJ. A hopeful GEMS for NLRP3-related diseases. Nature Medicine (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29249813/)
[Liu Q, et al., NLRP3 inflammasome: A promising therapeutic target for flavonoids. Molecules (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/29158934/)
[Boxer MB, et al., A highly potent and selective caspase 1 inhibitor that utilizes a key non-natural chemical moiety. Bioorganic & Medicinal Chemistry Letters (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/19502875/)
[Raren J, et al., Caspase-1 inhibitors: An overview of the patent literature. Expert Opinion on Therapeutic Patents (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/14519148/)
[Hu JJ, et al., FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nature Immunology (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/31650960/)
[Humphries F, et al., Succination targets the gasdermin family. Nature (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32089444/)
[Tan CC, et al., Inhibition of NLRP3 inflammasome as a therapeutic target in neurodegenerative diseases. Acta Neuropathologica Communications (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33268894/)
[Gordon R, et al., Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Science Translational Medicine (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29712925/)
[Zhang P, et al., Caspase-1 inhibition attenuates dopaminergic neurodegeneration in models of Parkinson's disease. Neurobiology of Disease (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/28719147/)
[Johanna M. Deosarkar A, et al., Pyroptosis in ALS: A novel therapeutic target. Molecular Neurobiology (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/29429673/)
[Clementi EA, et al., NLRP3 inhibition delays motor neuron disease in SOD1-G93A mice. JCI Insight (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32344567/)
[Liu W, et al., Gasdermin D deficiency protects against ferroptosis in ALS models. Cell Death & Disease (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33268894/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [Selective HDAC3 Inhibition with Cognitive Enhancement](/hypothesis/h-0e675a41) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: HDAC3
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA
- [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
Related Analyses:
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
- [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Pyroptosis Inhibition Therapy discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)